ClinicalTrials.gg
RecruitingNCT07234773Updated Mar 10, 2026

A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

A Phase 1 interventional study of KT501 in Rheumatoid Arthritis (RA), sponsored by Kali Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Kali Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Planned enrollment
133rd of 140
24 · median 469
Started
2026
with 8 others
Phase 1
21 of 154
12 open now
Primary completion
2027-02
later than 4 of 20 live
Registered
148th of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 133rd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 4 of the 20 other live ones, and was the 148th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).

Read the detailed description

This is a Phase 1, open-label, first-in-human dose escalation study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic of KT501 by a single subcutaneous administration in participants with Rheumatoid Arthritis (RA).

Up to a total of 5 cohorts with up to approximately 24 participants in total with RA will be enrolled. All participants will receive a single dose of KT501 on Day 1 and followed up until Week 12. For any participants with B cells lower than baseline level or lower limit quantification, whichever is lower, additional B cell follow up is required up to Week 48 after the study treatment.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis (RA)
  • Autoimmune
  • T-cell Engagers (TCEs)
  • B-cell Depletion
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old
  2. Diagnosis of adult-onset RA for at least 6 months
  3. Moderately to severely active RA
  4. Inadequate treatment response as defined in the protocol
  5. RF + or ACPA+
  6. Stable use of traditional DMARDs is permitted
  7. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Functional class IV as defined by the ACR Classification of Functional Status in RA
  2. Presence of any concomitant disease other than RA
  3. Active infection, history of serious recurrent or chronic infection
  4. History of progressive multifocal leukoencephalopathy
  5. Have a diagnosis or history of malignant disease within 5 years or breast cancer diagnosed within the previous 10 years.
  6. History of or planned organ transplant and/or or allogeneic hematopoietic stem cell transplantation
  7. Receipt of within 4 weeks
  8. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after study
  9. Women who are pregnant or breastfeeding
  10. Significant or uncontrolled medical disease that would preclude participant participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    KT501 Subcutaneous Injection Dose Level 1

    Drug: KT501

  • Experimental
    Dose Level 2

    KT501 Subcutaneous Injection Dose Level 2

    Drug: KT501

  • Experimental
    Dose Level 3

    KT501 Subcutaneous Injection Dose Level 3

    Drug: KT501

  • Experimental
    Dose Level 4

    KT501 Subcutaneous Injection Dose Level 4

    Drug: KT501

  • Experimental
    Dose Level 5

    KT501 Subcutaneous Injection Dose Level 5

    Drug: KT501

Interventions

  • DrugKT501

    KT501 is a monoclonal antibody that depletes B cells including plasma cells by targeting CD19, BCMA and CD3.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Incidence and severity of Adverse Events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Time frame: From Baseline Up to 12 weeks

  2. Incidence of Cytokine-release Syndrome (CRS)

    Incidence and severity of CRS with severity determined according to the 2019 American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus grading criteria

    Time frame: From Baseline Up to 12 Weeks

  3. Changes in Pulse Rate from Baseline

    Vital signs: Changes in Pulse Rate from Baseline

    Time frame: From Baseline Up to 12 Weeks

  4. Changes in Respiratory Rate from Baseline

    Vital Signs: Changes in Respiratory Rate from Baseline

    Time frame: From Baseline to 12 Weeks

  5. Changes in Blood Pressure from Baseline

    Vital Signs: Changes in Blood Pressure from Baseline

    Time frame: From Baseline Up to Week 12

  6. Changes in Temperature from Baseline

    Vital Signs: Changes in Body Temperature from Baseline

    Time frame: From Baseline to 12 Weeks

  7. Changes in Hematology Clinical Laboratory Results from Baseline

    Hematology: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

  8. Changes in Chemistry Clinical Laboratory Results from Baseline

    Chemistry: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

  9. Changes in Urinalysis Clinical Laboratory Results from Baseline

    Urinalysis: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

  10. Changes in Coagulation Clinical Laboratory Results from Baseline

    Coagulation: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

Secondary outcomes

  1. Serum Concentrations of KT501

    Blood samples will be collected at specific time points for calculating serum concentrations of KT501

    Time frame: Pre-dose and 6 hours post-dose on Day 1; Day 2, 3, 4, 5, 8, 11, 15, 22, 29, 43, 57 and 85.

  2. Incidence of Treatment-induced Anti-Drug Antibodies (ADAs)

    For Immunogenicity: Incidence of participants with treatment induced Anti-Drug Antibodies (ADA)

    Time frame: Pre-dose and on Day 1; Day 8, 11, 15, 22, 29, 43, 57 and 85.

  3. To Determine Cmax

    Maximum observed serum KT501 concentration

    Time frame: Day 1 - Day 85

  4. To Determine Tmax, Derived from Serum Concentration of each Dose of KT501

    Time to maximum observed concentration

    Time frame: Day 1 - Day 85

  5. Area Under the Serum-concentration Time Curve (AUC) from Time Zero to the Last Timepoint with Measurable Analyte Concentration (AUC0-t)

    Area under the concentration-time curve from 0 to the time of the last quantifiable concentration (AUClast)

    Time frame: Day 1 - Day 85

  6. AUC from Time Zero to Infinity (AUCinf)

    Area under the plasma concentration versus time curve (AUC) from time 0 extrapolated to infinity

    Time frame: Day 1 - Day 85

  7. To Determine Terminal Half-Life (T1/2)

    Terminal elimination half life summarized by dosing regimen

    Time frame: Day 1 - Day 85

  8. Total Body Clearance (CL/F)

    CL is the measure of the rate at which a drug is metabolized or eliminated by normal biological processes

    Time frame: Day 1 - Day 85

  9. Volume of Distribution During the Terminal Phase (Vz/F)

    Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.

    Time frame: Day 1 - Day 85

  10. Change in Levels of B Cell Count

    Pharmacodynamics: Change in levels of B cell counts measured at specific timepoints

    Time frame: Pre-dose on Day 1; Day 2, 3, 4, 5, 8, 11, 15, 22, 29, 43, 57 and 85.

  11. Duration of B Cell Depletion

    Pharmacodynamics: The duration of B cell depletion measured from Baseline

    Time frame: Day 1 - Day 85

  12. Change in Levels of Acute Inflammatory Markers

    Pharmacodynamics: Change in levels of acute Inflammatory markers (C-reactive protein (CRP) and CRS-related cytokines at specific timepoints

    Time frame: Pre-dose and 6 hours post-dose on Day 1; Day 2, 3, 4, 5, 8, 15, 22, 29,, 57 and 85.

  13. Changes in Blood Pressure from Baseline

    Vital Signs: Changes in Blood Pressure from Baseline

    Time frame: From Baseline to 12 Weeks

07

Study locations

1 of 1 sites recruiting
  • Kali Study Site
    Bayswater, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — This is a Phase 1 trial.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Feb 2027, 11 months later.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 11 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 18, 2025
StartEst.
Mar 6, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Aug 2027
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07234773
Lead sponsor
Kali Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Mar 6, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 10, 2026

Study contacts

Trial Information
Contact
clinical@kalitherapeutics.com
1-858-888-3080

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion